Hematology Research Center, Department of Radiation Oncology, Shiraz University of Medical Sciences, Iran.
Ann Hematol. 2010 Oct;89(10):993-1001. doi: 10.1007/s00277-010-0970-9. Epub 2010 May 4.
The present study aimed to define the natural history, World Health Organization (WHO) classification, prognostic factors, and treatment outcome of 87 patients with primary lymphoma of the palatine tonsil and literature review and analysis. Between 1990 and March 2008, 87 consecutive patients diagnosed with primary lymphoid malignancy of the palatine tonsil. All pathologic specimens were reviewed and reclassified according to the recent WHO classification. To investigate the association of tonsillar lymphomas with Epstein-Barr virus (EBV), in situ hybridization was performed for 24 tonsillar lymphomas (23 diffuse large B-cell lymphoma (DLBC) and one classic Hodgkin's disease) and ten normal tonsils as control group. In literature review, we found 26 major related series including 1,602 patients with primary tonsillar lymphoma. The median age of our patients was 52 years (range 11-86 years). There were 39 women and 48 men with a median follow-up of 67 months for living patients. The vast majority (95%) of patients had B-cell phenotype. DLBC was the most frequent histology. In situ hybridization revealed none of 23 DLBC to be positive for EBV. The 5-year disease-free and overall survival rates were 78.9% and 86%, respectively. In the literature review and by analyzing the data collection from 26 major reported series, the median age was 55 years and male/female ratio was 1.3:1. Intermediate grade tumors consisted of 72% of all tonsillar lymphomas and B-cell lymphomas constituted 82% of all cell immunophenotypes. The 5-year disease-free and overall survival rates were 61% and 67%, respectively. The vast majority of tonsillar lymphomas are of B-cell origin and with intermediate to high-grade histology. These neoplasms tend to present in early stage disease and to have favorable outcome. WHO classification predicts more accurately treatment outcome of patients with tonsillar lymphoma. The association of DLBC in the palatine tonsil with EBV infection is infrequent.
本研究旨在定义 87 例原发于腭扁桃体的淋巴瘤的自然病史、世界卫生组织(WHO)分类、预后因素和治疗结果,并进行文献复习和分析。1990 年至 2008 年 3 月,连续诊断为腭扁桃体原发性淋巴恶性肿瘤的 87 例患者。所有病理标本均经复习并根据最近的 WHO 分类重新分类。为了研究扁桃体淋巴瘤与 Epstein-Barr 病毒(EBV)的关系,对 24 例扁桃体淋巴瘤(23 例弥漫性大 B 细胞淋巴瘤(DLBC)和 1 例经典霍奇金病)和 10 例正常扁桃体进行了原位杂交,作为对照组。在文献复习中,我们发现 26 个主要相关系列,包括 1602 例原发于扁桃体的淋巴瘤患者。我们的患者中位年龄为 52 岁(范围 11-86 岁)。有 39 名女性和 48 名男性,存活患者的中位随访时间为 67 个月。绝大多数(95%)患者具有 B 细胞表型。DLBC 是最常见的组织学类型。原位杂交显示 23 例 DLBC 均未 EBV 阳性。5 年无病生存率和总生存率分别为 78.9%和 86%。在文献复习和分析 26 个主要报道系列的数据收集后,中位年龄为 55 岁,男女比例为 1.3:1。中间级别的肿瘤占所有扁桃体淋巴瘤的 72%,B 细胞淋巴瘤占所有细胞免疫表型的 82%。5 年无病生存率和总生存率分别为 61%和 67%。绝大多数扁桃体淋巴瘤来源于 B 细胞,且组织学分级为中高级别。这些肿瘤往往表现为早期疾病,预后良好。WHO 分类更准确地预测了扁桃体淋巴瘤患者的治疗结果。腭扁桃体 DLBC 与 EBV 感染的相关性不常见。